Evidence before a stack. Approval, benefit and risk depend on the specific compound and indication. Nervous-system coaching does not replace clinical assessment. Explore the 7-Day Reset and your matched The Recovery Protocol for optional wellbeing support, not permission to self-prescribe.
Thymosin Beta-4 fragment (Ac-LKKTETQ)
A repair story is not a repair trial.
TB-500 is marketed as a thymosin beta-4 fragment. Studies of full-length thymosin beta-4 cannot be borrowed as proof that the fragment heals human injuries. FDA reports no identified human exposure data for the LKKTETQ fragment and flags potential immunogenicity and impurities.
Evidence classification
Research context. Discussed in research or compounding-pharmacy contexts. Not broadly approved for general wellness use.
Evidence reviewed · 2026-10-21
TB-500 is marketed as a thymosin beta-4 fragment. Studies of full-length thymosin beta-4 cannot be borrowed as proof that the fragment heals human injuries. FDA reports no identified human exposure data for the LKKTETQ fragment and flags potential immunogenicity and impurities.
No established human recovery regimen or proven BPC-157 combination. Competitive athletes must check anti-doping rules; thymosin beta-4 and derivatives including TB-500 are prohibited at all times.
Before you layer this peptide
These are discussion points, not eligibility rules. No wearable score, supplement stack or thirty-day routine establishes that TB-500 is appropriate.
TB-500 is marketed as a thymosin beta-4 fragment. Studies of full-length thymosin beta-4 cannot be borrowed as proof that the fragment heals human injuries. FDA reports no identified human exposure data for the LKKTETQ fragment and flags potential immunogenicity and impurities.
No self-injection or experimental dosing instructions. Approved medicines follow their own label and prescriber plan.
| Clinical boundary | No established human recovery regimen or proven BPC-157 combination. Competitive athletes must check anti-doping rules; thymosin beta-4 and derivatives including TB-500 are prohibited at all times. |
Sourcing & quality
Use only lawfully supplied medicines for an appropriate indication, or a formally approved clinical trial. A research-use label or purity assay does not make a product suitable for human treatment. Ask a clinician or pharmacist to verify local authorization and availability; US approval alone does not establish access in Portugal.
Sleep, food, movement and symptom tracking are support pillars, not proven peptide enhancers. Supplements and devices can have their own risks; more is not automatically better.
Sleep and recovery
Track how you feel and function; sleep is support, not evidence that a peptide works.
Nutrition and movement
Individualize food and activity with your care team. Supplement combinations are not automatically necessary or safe.
Journal and clinician review
Record symptoms and treatment changes without assuming every change was caused by the molecule.
What does the current evidence support?
TB-500 is marketed as a thymosin beta-4 fragment. Studies of full-length thymosin beta-4 cannot be borrowed as proof that the fragment heals human injuries. FDA reports no identified human exposure data for the LKKTETQ fragment and flags potential immunogenicity and impurities.
Does an Anchor replace clinical care?
No. An Anchor offers optional coaching support. It is not a prescribing service, a safety certificate or a medical requirement before an approved treatment.
Where are the dosing instructions?
No established human recovery regimen or proven BPC-157 combination. Competitive athletes must check anti-doping rules; thymosin beta-4 and derivatives including TB-500 are prohibited at all times.
The matched Anchor
Optional coaching for the everyday habits around care. This Anchor does not establish peptide efficacy, authorize prescribing or replace medical treatment.
"You survived something hard. Give your body what it needs to come back."
Targets
Vagal Collapse
Category
Recovery
Fasting window
12:12 ONLY
Inside the full Anchor
Build the floor first
The Recovery Peptide Protocol sets the supplement, device, and fasting baseline this peptide is designed to layer on top of.
Medical disclaimer. Kokorology is an educational publication. The information on this page is not medical advice and does not establish a doctor-patient relationship. Peptides are pharmacologically active compounds. Several peptides referenced across this site are not approved by the FDA, EMA, or equivalent regulators for general wellness use; some are research compounds or approved only for narrow indications (e.g. tesamorelin for HIV-associated lipodystrophy). The FDA has issued warnings about unapproved compounded GLP-1 products. Never start, change, or stop a peptide protocol without a qualified prescriber. If you are pregnant, nursing, taking prescription medication, or have a chronic condition, do not begin any protocol described here without medical supervision.
TB-500 anchor protocol: tissue repair, dosing windows, and pairing with nervous-system regulation.
Human evidence, approval limits, new releases and safety boundaries. Experimental compounds are not established treatments; no self-injection or experimental dosing instructions.
Sleep, food, movement and symptom tracking support wellbeing alongside clinical care. An Anchor is optional coaching, not a medical prerequisite or proof of peptide efficacy.
Related reads: Anchor protocols, Blog, and — if you're already on a molecule — the matching Care package.
Evidence reviewed: 2026-10-21
TB-500 is marketed as a thymosin beta-4 fragment. Studies of full-length thymosin beta-4 cannot be borrowed as proof that the fragment heals human injuries. FDA reports no identified human exposure data for the LKKTETQ fragment and flags potential immunogenicity and impurities.
No established human recovery regimen or proven BPC-157 combination. Competitive athletes must check anti-doping rules; thymosin beta-4 and derivatives including TB-500 are prohibited at all times.